In early-stage lung cancer, the median survival was 69 months, with lower expression of AACT in patients with early lung cancer patients (n = 22) and with shorter survival; the median survival was 129.3 months, with higher expression of AACT in patients with early lung cancer (n = 57) with longer survival (Fig. 6C), which suggested that mRNA expression of AACT was strongly associated with the survival of patients. The gene discussed is SERPINA3; the disease is lung carcinoma.